Brain Monitoring Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device (EEG, EMG, MEG, ICP, MRI, fMRI, CT), By End-User (Hospitals, Neurology Centers, Clinics & ASC), By Application (Traumatic brain injury (TBI), Stroke, Dementia, Headache disorders, Sleep disorders, Parkinson disease, Epilepsy, Huntington disease, Other diseases), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.78 Billion
CAGR (2026-2031)	6.69%
Fastest Growing Segment	MRI
Largest Market	North America
Market Size (2031)	USD 5.57 Billion

Market Overview

The Global Brain Monitoring Market will grow from USD 3.78 Billion in 2025 to USD 5.57 Billion by 2031 at a 6.69% CAGR. The Global Brain Monitoring Market comprises medical devices and systems designed to measure and analyze neurological parameters, such as electrical activity and intracranial pressure, to assist in the diagnosis and management of brain disorders. Growth is primarily supported by the rising prevalence of neurological conditions and an aging population requiring critical care. According to the World Health Organization, in 2024, more than 3 billion people worldwide were living with a neurological condition, making these disorders the leading cause of illness and disability globally. This escalating disease burden directly amplifies the demand for effective diagnostic and monitoring interventions across acute and chronic care settings.

Despite these strong growth drivers, a significant challenge impeding market expansion is the substantial cost associated with advanced monitoring equipment and the complexity of reimbursement policies. Furthermore, the shortage of skilled neurologists and specialized healthcare personnel limits the widespread adoption of these technologies. This lack of expertise creates a bottleneck in interpreting complex physiological data, particularly in developing regions where healthcare infrastructure is often insufficient to support high-end medical devices.

Key Market Drivers

The escalating prevalence of neurodegenerative disorders and the expansion of the geriatric population stand as the primary catalysts for market growth. As the global population ages, the incidence of conditions such as dementia, Parkinson’s disease, and Alzheimer’s disease increases, necessitating frequent and precise neurological assessment. This demographic shift forces healthcare providers to adopt advanced monitoring systems for early diagnosis and continuous management to mitigate long-term care costs. According to the Alzheimer's Association, March 2024, in the '2024 Alzheimer's Disease Facts and Figures' report, an estimated 6.9 million Americans age 65 and older are living with Alzheimer's dementia. This surge in patient volume directly correlates with heightened utilization of electroencephalography (EEG) and other non-invasive monitoring modalities to track disease progression and treatment efficacy.

Technological advancements and the integration of artificial intelligence into neurodiagnostic tools further propel the adoption of brain monitoring solutions. Innovations in signal processing and machine learning enable devices to interpret complex physiological data with greater accuracy, attracting significant investment into the sector. For instance, according to Alto Neuroscience, February 2024, in the 'Alto Neuroscience Announces Closing of Initial Public Offering', the company secured approximately $128.6 million to advance their precision psychiatry platform, which utilizes EEG biomarkers. Such financial injections underscore the industry shift toward data-driven, personalized care. Moreover, broader spending on neurological infrastructure supports this technological integration. According to Medtronic, in 2024, their Neuroscience portfolio generated $9.4 billion in revenue, reflecting the substantial capital allocation toward advanced neurological interventions and monitoring capabilities globally.

Download Free Sample Report

Key Market Challenges

The shortage of skilled neurologists and specialized healthcare personnel constitutes a significant impediment to the expansion of the Global Brain Monitoring Market. Advanced brain monitoring systems generate complex physiological data that requires expert interpretation to be clinically useful. When healthcare facilities lack the trained staff necessary to operate these devices or analyze their outputs, the procurement of such equipment becomes difficult to justify. This deficit effectively caps market penetration, particularly in developing regions where the gap between the availability of medical technology and the workforce required to utilize it is most pronounced.

This workforce limitation directly counteracts the demand driven by the rising burden of neurological disease. According to the World Federation of Neurology, in 2024, low-income countries possessed up to 82 times fewer neurologists per 100,000 people compared to high-income nations. Such a severe disparity in specialized human resources restricts the ability of healthcare systems to implement comprehensive monitoring programs. Consequently, even as the prevalence of conditions requiring critical care rises, the market cannot reach its full potential because the essential expertise needed to deploy these diagnostic tools remains unavailable in vast segments of the global market.

Key Market Trends

The proliferation of wearable and portable brain monitoring devices is reshaping the market by moving diagnostics from specialized neurology departments to point-of-care settings like emergency rooms and intensive care units. Unlike bulky, traditional EEG carts that require complex setup, these compact systems allow clinicians to rapidly triage patients with suspected non-convulsive seizures or status epilepticus directly at the bedside. This accessibility significantly reduces time-to-diagnosis and improves workflow efficiency in acute care environments, driving rapid uptake among healthcare facilities. The demand for such agile solutions is evident in recent financial performance within the sector. According to Ceribell, November 2024, in the 'Third Quarter 2024 Financial Results', the company reported a 48% increase in total revenue to $17.2 million, driven by the expanding adoption of its portable, AI-enabled EEG system across hospital networks.

Concurrently, the expansion of tele-neurology and remote patient monitoring solutions is extending neuro-diagnostic capabilities beyond hospital walls, facilitating the management of chronic conditions such as epilepsy and sleep disorders in the home environment. This shift is fueled by the development of cloud-based platforms and Software-as-a-Medical-Device (SaMD) models that enable continuous data collection and remote physician review, effectively bridging the gap caused by specialist shortages. Manufacturers are increasingly pivoting toward these service-oriented revenue streams to capture the value of decentralized care. For instance, according to Compumedics Limited, September 2024, in the 'Business Update – FY24', the company achieved record revenues of $49.7 million, with growth significantly supported by its software-as-a-service (SaaS) remote monitoring division, which generated $4.2 million in revenue.

Segmental Insights

The Magnetic Resonance Imaging (MRI) segment is identified as the fastest-growing category within the Global Brain Monitoring Market. This rapid expansion is primarily driven by the increasing global prevalence of neurological disorders, such as traumatic brain injuries and strokes, which demand precise and non-invasive diagnostic solutions. Furthermore, significant technological advancements, including the development of functional MRI (fMRI), allow clinicians to visualize brain activity with superior clarity. Continuous product clearances by regulatory authorities, such as the U.S. Food and Drug Administration (FDA), further accelerate the adoption of these advanced imaging systems in clinical settings globally.

Regional Insights

North America maintains a dominant position in the global brain monitoring market, driven by the rising prevalence of neurological disorders and a well-established healthcare infrastructure. The region benefits from significant investments in medical research, with organizations like the National Institutes of Health supporting advancements in neurology. Additionally, the presence of key market players facilitates the availability of monitoring devices. Favorable reimbursement policies and rapid product approvals by the U.S. Food and Drug Administration further encourage clinical adoption. These structural advantages ensure North America remains the primary hub for brain monitoring technologies.

Recent Developments

• In November 2025, Ceribell, Inc. announced that it had received FDA 510(k) clearance for its Clarity algorithm for use in neonates. This regulatory clearance expanded the indication of the company's artificial intelligence-powered point-of-care electroencephalography system to include the detection of electrographic seizures in newborns, covering patients from pre-term infants to adults. The approval was supported by a substantial validation dataset and positioned the device as a critical tool for bedside seizure detection in neonatal intensive care units, where non-convulsive seizures often go undiagnosed. This development enabled clinicians to rapidly identify and manage neurological events in vulnerable infant populations.
• In February 2025, Medtronic plc obtained U.S. Food and Drug Administration approval for its BrainSense Adaptive Deep Brain Stimulation system. This approval marked the commercial introduction of the first closed-loop deep brain stimulation therapy capable of adjusting electrical stimulation in real-time based on the patient's sensed brain signals. The technology was designed to personalize treatment for Parkinson's disease by continuously monitoring neural activity and automatically modifying therapeutic delivery to maintain optimal symptom control. This advancement represented a significant shift towards data-driven, personalized neuromodulation, leveraging brain-computer interface technology to improve patient outcomes in the movement disorder market.
• In December 2024, Neuroelectrics entered into a strategic partnership with Neuronostics to develop an integrated electroencephalography solution tailored for pharmaceutical and medical device clinical trials. This collaboration combined Neuroelectrics' high-definition brain stimulation and hardware technology with Neuronostics' proprietary digital biomarkers and analytics platform. The alliance focused on streamlining neurological research by providing a unified system for data acquisition and analysis, which improved cohort identification and protocol design. By integrating these technologies, the companies sought to enhance the efficiency of clinical studies and accelerate the development of therapies for neurological conditions.
• In June 2024, Zeto, Inc. received FDA 510(k) clearance for its ONE EEG brain monitoring system, a portable device approved for use in hospital, home, ambulance, and air transport settings. This regulatory milestone introduced a user-friendly, dry-electrode headset designed to address the shortage of trained electroencephalography technologists by requiring minimal training for operation. The system features a camera for video-EEG and positions 21 soft-tip electrodes according to the standard 10-20 system, ensuring clinical accuracy. The launch aimed to democratize access to continuous neurological monitoring across various care environments, including intensive care units and emergency departments.

Key Market Players

• Drägerwerk AG & Co. KGaA
• Masimo Corporation
• Cadwell Industries, Inc.
• NuroWave Systems, Inc.
• Neurosoft SA
• CGX Systems
• Natus Medical, Inc.
• Nihon Kohden Corporation
• Koninklijke Philips N.V.
• GE HealthCare Technologies Inc.

By Device	By End-User	By Application	By Region
EEG EMG MEG ICP MRI fMRI CT	Hospitals Neurology Centers Clinics & ASC	Traumatic brain injury (TBI) Stroke Dementia Headache disorders Sleep disorders Parkinson disease Epilepsy Huntington disease Other diseases	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Brain Monitoring Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Brain Monitoring Market, By Device:

• EEG
• EMG
• MEG
• ICP
• MRI
• fMRI
• CT

• Brain Monitoring Market, By End-User:

• Hospitals
• Neurology Centers
• Clinics & ASC

• Brain Monitoring Market, By Application:

• Traumatic brain injury (TBI)
• Stroke
• Dementia
• Headache disorders
• Sleep disorders
• Parkinson disease
• Epilepsy
• Huntington disease
• Other diseases

• Brain Monitoring Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE